Hänvisningar gällande denna post

APA-referens (7:e uppl.)
Hara, M., Ohta, Y., Fusazaki, N., & Hirota, Y. (2024). Effectiveness of BNT162b2 Vaccine Against Symptomatic SARS-CoV-2 Infection in Children Aged 5–11 Years in Japan During Omicron Variant Predominate Periods. Japan Epidemiological Association.
Chicago-referens (17:e uppl.)
Hara, Megumi, Yuko Ohta, Naoki Fusazaki, och Yoshio Hirota. Effectiveness of BNT162b2 Vaccine Against Symptomatic SARS-CoV-2 Infection in Children Aged 5–11 Years in Japan During Omicron Variant Predominate Periods. Japan Epidemiological Association, 2024.
MLA-referens (9:e uppl.)
Hara, Megumi, et al. Effectiveness of BNT162b2 Vaccine Against Symptomatic SARS-CoV-2 Infection in Children Aged 5–11 Years in Japan During Omicron Variant Predominate Periods. Japan Epidemiological Association, 2024.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.